Key result
Aliskiren lowers BP comparably to major antihypertensives with a placebo-like side effect profile.
Why the study?
Aliskiren is the first orally active renin inhibitor approved for hypertension, but its cardiovascular benefits beyond blood pressure control remain to be demonstrated.
Is aliskiren effective and safe for lowering blood pressure in patients with hypertension?
Is aliskiren effective and safe for lowering blood pressure in patients with hypertension?
Aliskiren is the first orally active renin inhibitor approved for clinical use, providing effective blood pressure reduction with a favorable side effect profile.
Answers are grounded in this paper and cite their sources.
Aliskiren may be considered an alternative antihypertensive; leaves open its role in outcome trials.
Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg, there are dose-related falls in blood pressure comparable to those seen with other major classes of antihypertensive drugs and that these falls are associated with a placebo level of side effects. Aliskiren was found to be effective either as monotherapy or in combination with drugs from the other major classes. As expected, there was a greater benefit from adding aliskiren to natriuretic drugs than to other blockers of the renin system. However, there was also some consistent benefit from dual renin blockade. Aliskiren is likely to be of most value in patients uncontrolled by, or intolerant of, other classes. Rational understanding of the renin system will maximize its value, for instance, by encouraging greater use of natriuretic agents in patients with resistant hypertension to render their hypertension renin dependent. Whether there are cardiovascular benefits other than blood pressure control in blocking the renin system remains to be demonstrated. It is hoped that long-term outcome studies with aliskiren will finally allow this question to be answered.
No takes yet. Share an insight, caveat, or question.
Morris Jonathan Brown (2008) conducted a review in Hypertension. Aliskiren vs. Placebo or other antihypertensive drugs was evaluated. Aliskiren at doses of and provides dose-related reductions in blood pressure comparable to other major antihypertensive classes, with a placebo-like side effect profile.
Synapse has enriched 10 related papers. Consider them for comparative context: